One-year clinical experience on the use of Nintedanib in systemic sclerosis.
Respirol Case Rep
; 11(6): e01120, 2023 Jun.
Article
en En
| MEDLINE
| ID: mdl-37229296
ABSTRACT
We reviewed 11 patients with systemic sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non-specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Respirol Case Rep
Año:
2023
Tipo del documento:
Article